When she was a little girl, Maria Kitay remembers visiting her grandfather’s niece at St. Margaret’s Hospital, watching as the woman cried out in pain leaning against the wall of the hospital. Though breast cancer wasn’t spoken of at the time, Ms. Kitay, 67, now knows that was the disease afflicting not just her grandfather’s niece, but at least one other relative as well.
Thursday afternoon, Ms. Kitay stood in the auditorium of UPMC Magee-Women’s Hospital, a hospital bracelet still on her wrist, as the first participant in a study of a new breast cancer vaccine developed by UPMC and University of Pittsburgh researchers.
“Today, more than 30 years of research has brought us to the first of its kind clinical trial vaccine that could significantly change a breast cancer diagnosis,” said Elizabeth Wild, president of UPMC Hillman Cancer Center, at the press conference at UPMC Magee-Womens Hospital.
Ms. Kitay, of the North Hills, was diagnosed in February with “stage 0” breast cancer, ductal carcinoma in situ (DCIS). Her surgeon, Emilia Diego, told her about the opportunity to participate in the trial of the breast cancer vaccine, which targets patients before they develop full-blown breast cancer in hopes to priming the immune system to fight the cancer cells.
She received three injections of the vaccine within 10 weeks — her third shot administered Thursday morning prior to the press conference. She will proceed in two weeks with surgery and other standard treatments.
“This is one of the few trials that is actually targeting and developing a vaccine for people who are in stages where they have pre-invasive cancer,” said Dr. Diego, breast surgical oncologist at Magee-Womens. “Hopefully, the goal is down the line to be a vaccine for people who don't even have cancer.”
The study is hoping to recruit 50 women like Ms. Kitay who are willing to slightly delay surgery to test the cancer vaccine.
“We look forward to many more women signing up for this trial because this is a very innovative way to approach a breast cancer diagnosis, especially a pre-cancer diagnosis, where we can prevent it with the vaccine and eventually intercept it developing into cancer,” said lead researcher and Pitt distinguished professor of immunology and surgery Olivera Finn. “The long term goal is to prevent cancer and women who are participating in this trial are really going to help us combat it once and for all.”
Dr. Finn has been working on cancer vaccines since the 1980s, when she became the first researcher to identify an abnormal form of a protein common to cancer cells that was capable of generating an immune response. That protein, called MUC1, is the basis of the decades of research by Dr. Finn into cancer vaccines.
Funding for the study began with a $100,000 grant from McCandless-based Glimmer of Hope Foundation. The Breast Cancer Research Foundation added $2.1 million last year to expand the study.
Sometimes considered a “pre-cancer,” DCIS makes up about 20 to 25% of breast cancer diagnoses in the United States, and is often discovered by routine mammogram, as was the case for Ms. Kitay. If left treated, DCIS has a roughly 20 to 50% chance of developing invasive breast cancer, according to the Breast Cancer Research Foundation. It is usually removed surgically, either through a lumpectomy or mastectomy.
If the breast cancer vaccine shows promise, some of those surgeries may not be necessary, said Dr. Diego. “As we continue with the trial, we are hoping that once we see our response, maybe one day people will not need surgery because their immune system would have targeted these three invasive cells before they can become cancer,” she said.
Women diagnosed with DCIS interested in participating in the trial can contact UPMC Surgical Oncology at 412-641-3488.
Anya Sostek: asostek@post-gazette.com.







Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.